Latest news with #DrReddysLaboratories
Business Standard
5 days ago
- Business
- Business Standard
Dr Reddys Lab gains after Q1 PAT jumps 2% YoY to Rs 1,418 cr
Dr Reddys Laboratories added 2.52% to Rs 1,279.05 after the company's consolidated net profit rose 1.8% to Rs 1,418.10 crore on 11.4% increase in revenue from operations to Rs 8,545.20 crore in Q1 FY26 over Q1 FY25. Profit before tax (PBT) stood at Rs 1,905 crore in Q1 FY26, up 1.2% YoY EBITDA for the quarter stood at Rs 2,278.4 crore, up 5.49% YoY. In its global generics business, North America contributed Rs 3,412.3 crore in revenue, a 11% year-on-year decline. Revenue from Europe surged 142% to Rs 1,274.4 crore, The India business generated revenue of Rs 1,471.1 crore, registering an 11% YoY. Revenue from Pharmaceutical Services and Active Ingredients (PSAI) came in at Rs 818.1 crore, a 7% YoY increase. Co-Chairman & MD, G V Prasad, said: "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development." Hyderabad-based Dr. Reddys Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.
Reuters
5 days ago
- Business
- Reuters
India's equity benchmarks may open higher on UK trade deal, earnings optimism
July 24 (Reuters) - India's stock benchmarks will likely open marginally higher on Thursday, lifted by robust earnings from Infosys and optimism over a potential free-trade agreement with Britain. The Gift Nifty futures were trading at 25,298 points as of 7:57 a.m. IST, indicating that the Nifty 50 (.NSEI), opens new tab will open above Wednesday's close of 25,219.9. Broader Asian markets opened firm, tracking overnight gains on Wall Street after the U.S. and Japan announced a bilateral trade pact, which fuelled hopes of additional deals and lifted global risk appetite. Expectations that India and UK will sign a free-trade agreement on Thursday during Prime Minister Narendra Modi's visit to Britain further aided sentiment. The deal is expected to reduce tariffs on goods such as textiles, whisky and automobiles, while expanding market access for businesses. "A risk-on sentiment is prevailing across Asian markets, buoyed by favourable global cues following the announcement of a bilateral trade deal between the U.S. and Japan and supported by optimism surrounding the earnings season," Bajaj Broking Research said. On the domestic front, Infosys ( opens new tab will be in focus after India's second-largest IT services company raised the lower end of its full-year revenue guidance following a better-than-expected June quarter. Investors will also track market reaction to results from Dr Reddy's Laboratories ( opens new tab and Tata Consumer Products ( opens new tab. Dr Reddy's narrowly missed profit estimates due to pricing pressure and heightened competition in North America, while Tata Consumer posted a weak quarter as elevated tea and coffee prices weighed on margins. ** Coforge ( opens new tabposts, opens new tab sharp rise in quarterly profit, aided by a robust order book and large deal pipeline ** Bajaj Housing Finance ( opens new tab reports rise in quarterly profit on strong loan growth ** Persistent Systesm ( opens new tablogs, opens new tab rise in quarterly profit, revenue ** Key earnings on the day: Bajaj Finance ( opens new tab, Nestle India ( opens new tab, SBI Life ( opens new tab
Yahoo
5 days ago
- Business
- Yahoo
Dr. Reddy's Laboratories (RDY) and Alvotech Enter Into a Collaboration and License Agreement
Dr. Reddy's Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy's Laboratories Limited (NYSE:RDY) and Alvotech announced that they have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for the global markets. Just to provide a brief overview, Keytruda® (pembrolizumab) is indicated for treating numerous cancer types. A worker at a biopharmaceutical facility packaging an active pharmaceutical ingredient. This collaboration combines Dr. Reddy's Laboratories Limited (NYSE:RDY)'s and Alvotech's proven capabilities in biosimilars, which will help speed up the development process and extend the global reach for the biosimilar candidate. Dr. Reddy's Laboratories Limited (NYSE:RDY)'s top management believes that the collaboration reflects its ability to develop and manufacture high-quality and affordable treatment options. Furthermore, oncology remains a top focus therapy area, and this collaboration is expected to further enhance its capabilities in oncology, with pembrolizumab representing one of the most critical therapies in immuno-oncology. Dr. Reddy's Laboratories Limited (NYSE:RDY) reported its financial results for the quarter and year ended March 31, 2025. It saw double-digit growth across its businesses, thanks to the successful product launches, higher revenues from key products in the US, and the integration of the acquired NRT business. Its FY 2025 consolidated revenues came in at INR325.5 billion, reflecting YoY growth of 17%. Its underlying revenue growth, excluding NRT business, stood at 12% YoY. Headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited (NYSE:RDY) operates as an integrated pharmaceutical company. While we acknowledge the potential of RDY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Reuters
6 days ago
- Business
- Reuters
Dr Reddy's kicks off India big pharma earnings with profit miss
July 23 (Reuters) - Indian generic drugs maker Dr Reddy's Laboratories ( opens new tab missed quarterly profit expectations on Wednesday, as it struggled with pricing pressure on drugs and stiff competition in its key North America market. The company's consolidated net profit increased to 14.18 billion rupees ($164.2 million) in the quarter ended June 30, below analysts' estimate of 14.94 billion rupees, as per data compiled by LSEG. ($1 = 86.3800 Indian rupees)
Business Standard
26-05-2025
- Business
- Business Standard
Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA
Dr Reddys Laboratories said that the United States Food & Drug Administration (US FDA), post a GMP inspection, has issued a Form 483 with 2 observations to the company's Telangana-based manufacturing facility. In a regulatory filing made on Saturday (24 May 2025), the company informed that the US FDA had conducted a GMP inspection at its API manufacturing facility in Miryalaguda, Telangana, India. The inspection was conducted from 19 May 2025 to 24 May 2025. Post the inspection, the American regulatory agency has issued a Form 483 with 2 observations. The pharmaceutical company stated that it would address the said observation from the US FDA within the stipulated timeline. Hyderabad-based Dr. Reddys Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The company reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year increase from Rs 1,307 crore in the same period last year. Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24. The scrip rose 0.46% to currently trade at Rs 1235.40 on the BSE.
